Literature DB >> 19278576

A long-term follow-up of botulinum toxin A in cervical dystonia.

B Mohammadi1, N Buhr, H Bigalke, K Krampfl, R Dengler, K Kollewe.   

Abstract

OBJECTIVE: Cervical dystonia (CD) is the most common form of adult-onset focal dystonia, and botulinum toxin A (BoNT-A) has become the first-line treatment for this condition.
METHODS: In this work, we present data of 207 CD patients treated with BoNT-A for 6.7 +/- 3.5 years. One hundred and sixty-three patients were treated with Dysport (mean dose, 389 +/- 144 U) and 44 with Botox (mean dose, 145 +/- 44 U).
RESULTS: The mean clinical benefit, based on a 0-3 scale (0=no effect, 1=slight, 2=moderate and 3=marked improvement) was similar for Dysport (2.5 +/- 0.3) and Botox (2.2 +/- 0.4). Adverse events were mild and similar for both products. Fewer than 2% of the patients developed neutralizing antibodies. DISCUSSION: These data confirm the efficacy and safety of BoNT-A treatment in CD over an extended period of up to 14 years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19278576     DOI: 10.1179/174313209X405137

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  33 in total

1.  [Use of botulinum toxin in ORL departments in Germany].

Authors:  P Matthes; J Kruegel; C Karapantzou; J Winterhoff; R Laskawi
Journal:  HNO       Date:  2010-05       Impact factor: 1.284

2.  Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.

Authors:  A R Bentivoglio; E Di Stasio; D Mulas; M L Cerbarano; T Ialongo; A Laurienzo; Martina Petracca
Journal:  Neurotox Res       Date:  2017-05-06       Impact factor: 3.911

3.  Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.

Authors:  Joaquim J Ferreira; Roongroj Bhidayasiri; Carlo Colosimo; Maria Jose Marti; Benjamin Zakine; Pascal Maisonobe
Journal:  Funct Neurol       Date:  2012 Oct-Dec

4.  Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.

Authors:  Katja Kollewe; Bahram Mohammadi; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-05-01       Impact factor: 3.575

Review 5.  Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis.

Authors:  Margherita Fabbri; Giorgio Leodori; Ricardo M Fernandes; Roongroj Bhidayasiri; Maria Jose Marti; Carlo Colosimo; Joaquim J Ferreira
Journal:  Neurotox Res       Date:  2016-01       Impact factor: 3.911

Review 6.  Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.

Authors:  Maria Fiorella Contarino; Joost Van Den Dool; Yacov Balash; Kailash Bhatia; Nir Giladi; Johannes H Koelman; Annemette Lokkegaard; Maria J Marti; Miranda Postma; Maja Relja; Matej Skorvanek; Johannes D Speelman; Evelien Zoons; Joaquim J Ferreira; Marie Vidailhet; Alberto Albanese; Marina A J Tijssen
Journal:  Front Neurol       Date:  2017-02-24       Impact factor: 4.003

7.  Clinical Characteristics and Response to Long-Term Botulinum Toxin Type A Therapy in Patients with Cervical Dystonia at a Neurology Clinic.

Authors:  Aysu Şen; Aysun Soysal; Baki Arpaci
Journal:  Noro Psikiyatr Ars       Date:  2014-12-01       Impact factor: 1.339

8.  Use of injectable spasticity management agents in a cancer center.

Authors:  Jack Fu; Carolina Gutiérrez; Eduardo Bruera; Ying Guo; Shana Palla
Journal:  Support Care Cancer       Date:  2012-11-11       Impact factor: 3.603

9.  Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.

Authors:  Katja Kollewe; Bahram Mohammadi; Steffen Köhler; Heidrun Pickenbrock; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2014-07-25       Impact factor: 3.575

Review 10.  Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?

Authors:  H A Jinnah; Cynthia L Comella; Joel Perlmutter; Codrin Lungu; Mark Hallett
Journal:  Toxicon       Date:  2017-09-06       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.